Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Isofol Medical AB ( (SE:ISOFOL) ).
Isofol Medical AB has successfully completed the first cohort in its phase Ib/II clinical study of arfolitixorin, a potential treatment for metastatic colorectal cancer, at Charité – Universitätsmedizin Berlin. The positive recommendation from the Safety Review Committee allows Isofol to proceed to the next dose cohort, marking a significant milestone in the study’s progression and potentially impacting the treatment landscape for colorectal cancer.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company focused on improving the quality of life and prognosis for patients with severe forms of cancer. The company is developing arfolitixorin, a drug candidate aimed at enhancing the efficacy of first-line standard treatments for various solid tumors, particularly in colorectal cancer, which is the third most common cancer worldwide.
Average Trading Volume: 615,826
Current Market Cap: SEK176.9M
For a thorough assessment of ISOFOL stock, go to TipRanks’ Stock Analysis page.